Home/Strides Pharma/R. Ananthanarayanan (Ananth)
RA

R. Ananthanarayanan (Ananth)

Managing Director and CEO

Strides Pharma

Strides Pharma Pipeline

DrugIndicationPhase
Biosimilar AdalimumabAutoimmune Diseases (e.g., Rheumatoid Arthritis)Development
Biosimilar BevacizumabOncology (Various Cancers)Development
Biosimilar TrastuzumabOncology (HER2+ Breast Cancer)Development
Biosimilar PegfilgrastimOncology (Neutropenia)Development
Complex Generic PortfolioVarious (CNS, CVS, Anti-infectives)ANDA Filed/Approved
Starflu (Oseltamivir)InfluenzaMarketed
HIV/AIDS, TB, Malaria PortfolioInfectious DiseasesMarketed